Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R209130 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| R209130 | DRUG | - |
Inclusion: * Adults aged 18-60 * Current diagnosis of schizophrenia * Significant negative symptoms with few positive symptoms (e.g. hallucinations, delusions) and no evidence of major depression. * Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment...
R209130 is an investigational small molecule being studied for the treatment of schizophrenia. It is currently in Phase 2 clinical development, with one completed trial evaluating its safety and efficacy for negative symptoms of schizophrenia.
R209130 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research to evaluate the drug's potential in treating schizophrenia.
R209130 is in Phase 2 clinical development. One Phase 2 trial has been completed, and the drug is not yet approved by regulatory authorities. It remains investigational and is being studied for its safety and efficacy in patients with schizophrenia.
R209130 has one completed clinical trial registered as NCT00063297, titled 'Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia.' This Phase 2 study enrolled 180 participants in the United States and was randomized and double-blind.
R209130 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for schizophrenia. The completed trial NCT00063297 evaluated its safety and efficacy, but the drug has not yet received regulatory approval.